Cargando…
Autoreactivity against Denatured Type III Collagen Is Significantly Decreased in Serum from Patients with Cancer Compared to Healthy Controls
Autoantibodies have the potential as cancer biomarkers as they may associate with the outcome and immune-related adverse events (irAEs) following immunotherapy. Cancer and other fibroinflammatory diseases, such as rheumatoid arthritis (RA), are associated with excessive collagen turnover leading to...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139183/ https://www.ncbi.nlm.nih.gov/pubmed/37108227 http://dx.doi.org/10.3390/ijms24087067 |
_version_ | 1785032885482291200 |
---|---|
author | Jensen, Christina Drobinski, Patryk Thorlacius-Ussing, Jeppe Karsdal, Morten A. Bay-Jensen, Anne-Christine Willumsen, Nicholas |
author_facet | Jensen, Christina Drobinski, Patryk Thorlacius-Ussing, Jeppe Karsdal, Morten A. Bay-Jensen, Anne-Christine Willumsen, Nicholas |
author_sort | Jensen, Christina |
collection | PubMed |
description | Autoantibodies have the potential as cancer biomarkers as they may associate with the outcome and immune-related adverse events (irAEs) following immunotherapy. Cancer and other fibroinflammatory diseases, such as rheumatoid arthritis (RA), are associated with excessive collagen turnover leading to collagen triple helix unfolding and denaturation with exposure of immunodominant epitopes. In this study, we aimed to investigate the role of autoreactivity against denatured collagen in cancer. A technically robust assay to quantify autoantibodies against denatured type III collagen products (anti-dCol3) was developed and then measured in pretreatment serum from 223 cancer patients and 33 age-matched controls. Moreover, the association between anti-dCol3 levels and type III collagen degradation (C3M) and formation (PRO-C3) was investigated. Anti-dCol3 levels were significantly lower in patients with bladder (p = 0.0007), breast (p = 0.0002), colorectal (p < 0.0001), head and neck (p = 0.0005), kidney (p = 0.005), liver (p = 0.030), lung (p = 0.0004), melanoma (p < 0.0001), ovarian (p < 0.0001), pancreatic (p < 0.0001), prostate (p < 0.0001), and stomach cancers (p < 0.0001) compared to controls. High anti-dCol3 levels were associated with type III collagen degradation (C3M, p = 0.0002) but not type III collagen formation (PRO-C3, p = 0.26). Cancer patients with different solid tumor types have downregulated levels of circulating autoantibodies against denatured type III collagen compared to controls, suggesting that autoreactivity against unhealthy type III collagen may be important for tumor control and eradication. This autoimmunity biomarker may have the potential for studying the close relationship between autoimmunity and cancer. |
format | Online Article Text |
id | pubmed-10139183 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101391832023-04-28 Autoreactivity against Denatured Type III Collagen Is Significantly Decreased in Serum from Patients with Cancer Compared to Healthy Controls Jensen, Christina Drobinski, Patryk Thorlacius-Ussing, Jeppe Karsdal, Morten A. Bay-Jensen, Anne-Christine Willumsen, Nicholas Int J Mol Sci Article Autoantibodies have the potential as cancer biomarkers as they may associate with the outcome and immune-related adverse events (irAEs) following immunotherapy. Cancer and other fibroinflammatory diseases, such as rheumatoid arthritis (RA), are associated with excessive collagen turnover leading to collagen triple helix unfolding and denaturation with exposure of immunodominant epitopes. In this study, we aimed to investigate the role of autoreactivity against denatured collagen in cancer. A technically robust assay to quantify autoantibodies against denatured type III collagen products (anti-dCol3) was developed and then measured in pretreatment serum from 223 cancer patients and 33 age-matched controls. Moreover, the association between anti-dCol3 levels and type III collagen degradation (C3M) and formation (PRO-C3) was investigated. Anti-dCol3 levels were significantly lower in patients with bladder (p = 0.0007), breast (p = 0.0002), colorectal (p < 0.0001), head and neck (p = 0.0005), kidney (p = 0.005), liver (p = 0.030), lung (p = 0.0004), melanoma (p < 0.0001), ovarian (p < 0.0001), pancreatic (p < 0.0001), prostate (p < 0.0001), and stomach cancers (p < 0.0001) compared to controls. High anti-dCol3 levels were associated with type III collagen degradation (C3M, p = 0.0002) but not type III collagen formation (PRO-C3, p = 0.26). Cancer patients with different solid tumor types have downregulated levels of circulating autoantibodies against denatured type III collagen compared to controls, suggesting that autoreactivity against unhealthy type III collagen may be important for tumor control and eradication. This autoimmunity biomarker may have the potential for studying the close relationship between autoimmunity and cancer. MDPI 2023-04-11 /pmc/articles/PMC10139183/ /pubmed/37108227 http://dx.doi.org/10.3390/ijms24087067 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Jensen, Christina Drobinski, Patryk Thorlacius-Ussing, Jeppe Karsdal, Morten A. Bay-Jensen, Anne-Christine Willumsen, Nicholas Autoreactivity against Denatured Type III Collagen Is Significantly Decreased in Serum from Patients with Cancer Compared to Healthy Controls |
title | Autoreactivity against Denatured Type III Collagen Is Significantly Decreased in Serum from Patients with Cancer Compared to Healthy Controls |
title_full | Autoreactivity against Denatured Type III Collagen Is Significantly Decreased in Serum from Patients with Cancer Compared to Healthy Controls |
title_fullStr | Autoreactivity against Denatured Type III Collagen Is Significantly Decreased in Serum from Patients with Cancer Compared to Healthy Controls |
title_full_unstemmed | Autoreactivity against Denatured Type III Collagen Is Significantly Decreased in Serum from Patients with Cancer Compared to Healthy Controls |
title_short | Autoreactivity against Denatured Type III Collagen Is Significantly Decreased in Serum from Patients with Cancer Compared to Healthy Controls |
title_sort | autoreactivity against denatured type iii collagen is significantly decreased in serum from patients with cancer compared to healthy controls |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139183/ https://www.ncbi.nlm.nih.gov/pubmed/37108227 http://dx.doi.org/10.3390/ijms24087067 |
work_keys_str_mv | AT jensenchristina autoreactivityagainstdenaturedtypeiiicollagenissignificantlydecreasedinserumfrompatientswithcancercomparedtohealthycontrols AT drobinskipatryk autoreactivityagainstdenaturedtypeiiicollagenissignificantlydecreasedinserumfrompatientswithcancercomparedtohealthycontrols AT thorlaciusussingjeppe autoreactivityagainstdenaturedtypeiiicollagenissignificantlydecreasedinserumfrompatientswithcancercomparedtohealthycontrols AT karsdalmortena autoreactivityagainstdenaturedtypeiiicollagenissignificantlydecreasedinserumfrompatientswithcancercomparedtohealthycontrols AT bayjensenannechristine autoreactivityagainstdenaturedtypeiiicollagenissignificantlydecreasedinserumfrompatientswithcancercomparedtohealthycontrols AT willumsennicholas autoreactivityagainstdenaturedtypeiiicollagenissignificantlydecreasedinserumfrompatientswithcancercomparedtohealthycontrols |